Literature DB >> 9379000

Dual role of IL-12 in early and late stages of murine collagen type II arthritis.

L A Joosten1, E Lubberts, M M Helsen, W B van den Berg.   

Abstract

IL-12 can promote Th1 responses, and early administration of IL-12 during immunization was shown to enhance expression of autoimmune collagen-induced arthritis (CIA). We now studied the impact of IL-12 at the stage of disease expression and during established CIA in DBA-1 mice. Accelerated onset and enhanced severity were provoked when i.p. injections of 100 ng of murine IL-12 (mIL-12) were given around the time of arthritis onset. Moreover, the onset of CIA could be ameliorated with anti-mIL-12 Abs, indicating that IL-12 is a pivotal mediator in the expression of CIA. In addition, the effect of anti-mIL-12 treatment was analyzed in established CIA. Continued treatment did not suppress established arthritis. Instead, these mice showed an impressive exacerbation of arthritis shortly after cessation of anti-mIL-12 treatment, indicative of impairment of endogenous control. Exaggerated disease was characterized by massive granulocyte influx and enhanced expression of IL-1 beta and TNF-alpha mRNA in the synovial tissue. Subsequently, we treated established collagen arthritis with recombinant mIL-12 for 7 days. Profound suppression of the arthritis score was noted, including reduced influx of cells and diminished cartilage damage. Tenfold enhanced levels of IL-10 were detected in sera of mIL-12-treated mice, and up-regulated mRNA levels of IL-10, IFN-gamma, and IL-12 were measured in synovial tissue. Finally, the anti-inflammatory effect of IL-12 on CIA could be reversed by coadministration of anti-IL-10 Abs. This study indicates that IL-12 has a stimulatory role in early arthritis expression, whereas it has a suppressive role in the established phase of collagen arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379000

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Host resistance against Candida alibcans infection in mice with adjuvant induced arthritis.

Authors:  Martin Yordanov; Anna Deleva; Nina Ivanovska
Journal:  Mycopathologia       Date:  2002       Impact factor: 2.574

2.  Blockade of endogenous interleukin 12 results in suppression of murine streptococcal cell wall arthritis by enhancement of interleukin 10 and interleukin 1Ra.

Authors:  L A Joosten; M M Helsen; W B van Den Berg
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 3.  Adhesion molecules in inflammatory diseases: insights from knockout mice.

Authors:  Daniel C Bullard
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF.

Authors:  I K Campbell; K O'Donnell; K E Lawlor; I P Wicks
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 5.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 6.  Evidence that cytokines play a role in rheumatoid arthritis.

Authors:  Fionula M Brennan; Iain B McInnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 7.  Parasitic helminths: new weapons against immunological disorders.

Authors:  Yoshio Osada; Tamotsu Kanazawa
Journal:  J Biomed Biotechnol       Date:  2010-02-10

Review 8.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 9.  Joint inflammation and cartilage destruction may occur uncoupled.

Authors:  W B van den Berg
Journal:  Springer Semin Immunopathol       Date:  1998

Review 10.  FLT3 inhibitors for the treatment of autoimmune disease.

Authors:  Katharine A Whartenby; Donald Small; Peter A Calabresi
Journal:  Expert Opin Investig Drugs       Date:  2008-11       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.